Leukemia Therapeutics Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032
Description
Leukemia Therapeutics Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032
Growth Factors of Leukemia Therapeutics Market
The Leukemia Therapeutics market was valued at USD 15.21 billion in 2023, and the market is now projected to grow from USD 16.15 billion in 2024 to USD 27.78 billion by 2032, exhibiting a CAGR of 8.1% during the forecast period of 2024-2032.
The diminish in non-COVID patients in clinics come about in decays in strategies and medicines for disease medications. Besides, a think about conducted by the U.K. Coronavirus Cancer Monitoring Project (UKCCMP) detailed that blood cancer patients, particularly those enduring from leukemia, different myeloma, and lymphoma, are at a better chance of getting affected by the COVID infection, which is able increment the request for leukemia therapeutics. Be that as it may, the medications for basic infections, such as cancers, cardiovascular conditions, and other genuine conditions, have been performed frequently. The COVID-19 widespread has had a constrained effect on the deals created by leukemia therapeutic products infuriating the market growth.
There are a number of inquire about exercises being conducted to create distinctive sorts of treatment approaches, utilizing combinations of different treatments to progress quiet results for distinctive sorts of leukemia. Also, the common executioner cell-based immunotherapy for AML is one of the treatment choices for the handling of neglected clinical needs. Besides, the inquire about group at the German Center for Neurodegenerative Maladies (DZNE) and the College of Bonn has created an artificial insights (AI) device that tracks and recognizes intense myeloid leukemia with tall unwavering quality. The improvement of such imaginative demonstrative and therapeutics for leukemia patients is anticipated to upgrade leukemia therapeutics market growth amid the forecasted period.
One of the first driving components impacting the worldwide advertise is the expanding predominance of leukemia over the globe, which is anticipated to fuel the request for leukemia therapeutics. Almost all sorts of leukemia, such as ALL and CML, are seeing an expanded predominance universally. Such an increment in persistent populaces over the world is anticipated to boost the development of the market.
Comprehensive Analysis of Leukemia Therapeutics Market
On the bifurcation of the type of analysis of Leukemia, the market for leukemia therapeutics is sectioned as CML, AML, CLL and ALL. Of all the four segmentations the part CLL is termed to be the most dominant part with increasing demand from patients demanding treatment suffering from this type of condition. The nodes of treatment type analysis are sectioned as Immunotherapy, chemotherapy and targeted therapy. The part chemotherapy with the first line of treatment is pivotal treatment dominating the market growth. Oral and injectable are the two fractions of route of administration. With quick absorbing properties and providence of quick outcomes the mode injectable is proved to be the most utilized segment.
With a proven outstanding valuation of USD 6.92 billion, the Leukemia therapeutics market share in the global market is ruling out in the North American region. The region’s dominance is proved with a strong healthcare infrastructure and the nations willingness in expenditure. Moreover, with the presence of key manufacturers in the development of Leukemia products with extensive analysis and research by the nation in the market globally prove its dominance.
The market for the Leukemia Therapeutics is majorly comprised of the prominent players that are operating intensively in the market, proving their existence and profitable revenues with the extensive research and innovative practices and product development. The market players lined up are as follows: Pfizer Inc. (U.S.), Novartis (Switzerland), Lupin Ltd. (India), Amgen Inc. (U.S.), AbbVie (U.S.), Johnson & Johnson Services, Inc. (U.S.), Bristol-Myers Squibb (U.S.), F. Hoffmann-La Roche (Switzerland), Takeda Pharmaceutical Co Ltd (Japan) and Sanofi/ Genzyme Corporation (France) are dedicatedly working towards the intensive research and development of the innovation in manufacturing and launching Leukemia Therapeutics products enriched with more health benefits and maximum nutrient absorption.
In the month of April 2021, Bristol-Myers Squibb company declared that the Committee for Therapeutic Items for Human Utilize (CHMP) of the European Solutions Organization has prescribed endorsement for their sedate Onureg for Verbal Support Treatment for the treatment of patients with Intense Myeloid Leukemia.
SEGMENTATION TABLE
ATTRIBUTE DETAILS
Study Period 2016-2027
Base Year 2019
Forecast Period 2020-2027
Historical Period 2016-2018
Unit Value (USD Billion)
Segmentation Type of Leukemia, Treatment Type, Route of Administration, Distribution Channels, and Geography
By Type of Leukemia
Chronic Myeloid Leukemia (CML)
Chronic Lymphocytic Leukemia (CLL)
Acute Lymphocytic Leukemia (ALL)
Acute Myeloid Leukemia (AML)
Others
By Treatment Type
Chemotherapy
Targeted Therapy
Immunotherapy
Others
By Route of Administration
Oral
Injectable
By Distribution Channels
Hospital Pharmacy
Retail Pharmacy
Others
By Geography
North America
By Type of Leukemia
By Treatment Type
By Route of Administration
By Distribution Channels
By Country
The U.S. (By Type of Leukemia)
Canada (By Type of Leukemia)
Europe
By Type of Leukemia
By Treatment Type
By Route of Administration
By Distribution Channels
By Country/ Sub-Region
The U.K. (By Type of Leukemia)
Germany (By Type of Leukemia)
France (By Type of Leukemia)
Italy (By Type of Leukemia)
Spain (By Type of Leukemia)
Rest of Europe (By Type of Leukemia)
Asia Pacific
By Type of Leukemia
By Treatment Type
By Route of Administration
By Distribution Channels
By Country/ Sub-Region
Japan (By Type of Leukemia)
China (By Type of Leukemia)
India (By Type of Leukemia)
Australia (By Type of Leukemia)
Rest of Asia Pacific (By Type of Leukemia)
Latin America
By Type of Leukemia
By Treatment Type
By Route of Administration
By Distribution Channels
By Country/ Sub-Region
Brazil (By Type of Leukemia)
Mexico (By Type of Leukemia)
Rest of Latin America (By Type of Leukemia)
The Middle East & Africa
By Type of Leukemia
By Treatment Type
By Route of Administration
By Distribution Channels
By Country/ Sub-Region
GCC (By Type of Leukemia)
South Africa (By Type of Leukemia)
Rest of the Middle East & Africa (By Type of Leukemia)
Table of Contents
140 Pages
- 1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
- 2. Executive Summary
- 3. Market Dynamics
- 3.1. Market Drivers
- 3.2. Market Restraints
- 3.3. Market Opportunities
- 4. Key Insights
- 4.1. Pipeline Analysis, Key Players
- 4.2. Prevalence of Leukemia, Key Countries, 2019
- 4.3. Key Industry Developments (Mergers, Acquisition, etc.)
- 4.4. Impact of Covid-19 on the Leukemia Therapeutics Market
- 5. Global Leukemia Therapeutics Market Analysis, Insights and Forecast, 2016-2027
- 5.1. Key Findings / Summary
- 5.2. Market Analysis, Insights and Forecast – By Type of Leukemia
- 5.2.1. Chronic Myeloid Leukemia (CML)
- 5.2.2. Chronic Lymphocytic Leukemia (CLL)
- 5.2.3. Acute Lymphocytic Leukemia (ALL)
- 5.2.4. Acute Myeloid Leukemia (AML)
- 5.2.5. Others
- 5.3. Market Analysis, Insights and Forecast – By Treatment Type
- 5.3.1. Chemotherapy
- 5.3.2. Targeted Therapy
- 5.3.3. Immunotherapy
- 5.3.4. Others
- 5.4. Market Analysis, Insights and Forecast – By Route of Administration
- 5.4.1. Injectable Mode
- 5.4.2. Oral Mode
- 5.5. Market Analysis, Insights and Forecast – By Distribution Channel
- 5.5.1. Hospital Pharmacies
- 5.5.2. Retail Pharmacies
- 5.5.3. Others
- 5.6. Market Analysis, Insights and Forecast – By Region
- 5.6.1. North America
- 5.6.2. Europe
- 5.6.3. Asia pacific
- 5.6.4. Latin America
- 5.6.5. Middle East & Africa
- 6. North America Leukemia Therapeutics Market Analysis, Insights and Forecast, 2016-2027
- 6.1. Key Findings / Summary
- 6.2. Market Analysis – By Type of Leukemia
- 6.2.1. Chronic Myeloid Leukemia (CML)
- 6.2.2. Chronic Lymphocytic Leukemia (CLL)
- 6.2.3. Acute Lymphocytic Leukemia (ALL)
- 6.2.4. Acute Myeloid Leukemia (AML)
- 6.2.5. Others
- 6.3. Market Analysis – By Treatment Type
- 6.3.1. Chemotherapy
- 6.3.2. Targeted Therapy
- 6.3.3. Immunotherapy
- 6.3.4. Others
- 6.4. Market Analysis – By Route of Administration
- 6.4.1. Injectable Mode
- 6.4.2. Oral Mode
- 6.5. Market Analysis – By Distribution Channel
- 6.5.1. Hospital Pharmacies
- 6.5.2. Retail Pharmacies
- 6.5.3. Others
- 6.6. Market Analysis – By Country
- 6.6.1. U.S.
- 6.6.2. Canada
- 7. Europe Leukemia Therapeutics Market Analysis, Insights and Forecast, 2016-2027
- 7.1. Key Findings / Summary
- 7.2. Market Analysis – By Type of Leukemia
- 7.2.1. Chronic Myeloid Leukemia (CML)
- 7.2.2. Chronic Lymphocytic Leukemia (CLL)
- 7.2.3. Acute Lymphocytic Leukemia (ALL)
- 7.2.4. Acute Myeloid Leukemia (AML)
- 7.2.5. Others
- 7.3. Market Analysis – By Treatment Type
- 7.3.1. Chemotherapy
- 7.3.2. Targeted Therapy
- 7.3.3. Immunotherapy
- 7.3.4. Others
- 7.4. Market Analysis – By Route of Administration
- 7.4.1. Injectable Mode
- 7.4.2. Oral Mode
- 7.5. Market Analysis – By Distribution Channel
- 7.5.1. Hospital Pharmacies
- 7.5.2. Retail Pharmacies
- 7.5.3. Others
- 7.6. Market Analysis – By Country/Sub-Region
- 7.6.1. U.K.
- 7.6.2. Germany
- 7.6.3. France
- 7.6.4. Spain
- 7.6.5. Italy
- 7.6.6. Rest of Europe
- 8. Asia Pacific Leukemia Therapeutics Market Analysis, Insights and Forecast, 2016-2027
- 8.1. Key Findings / Summary
- 8.2. Market Analysis – By Type of Leukemia
- 8.2.1. Chronic Myeloid Leukemia (CML)
- 8.2.2. Chronic Lymphocytic Leukemia (CLL)
- 8.2.3. Acute Lymphocytic Leukemia (ALL)
- 8.2.4. Acute Myeloid Leukemia (AML)
- 8.2.5. Others
- 8.3. Market Analysis – By Treatment Type
- 8.3.1. Chemotherapy
- 8.3.2. Targeted Therapy
- 8.3.3. Immunotherapy
- 8.3.4. Others
- 8.4. Market Analysis – By Route of Administration
- 8.4.1. Injectable Mode
- 8.4.2. Oral Mode
- 8.5. Market Analysis – By Distribution Channel
- 8.5.1. Hospital Pharmacies
- 8.5.2. Retail Pharmacies
- 8.5.3. Others
- 8.6. Market Analysis – By Country/Sub-Region
- 8.6.1. Japan
- 8.6.2. China
- 8.6.3. India
- 8.6.4. Australia
- 8.6.5. Rest of Asia Pacific
- 9. Latin America Leukemia Therapeutics Market Analysis, Insights and Forecast, 2016-2027
- 9.1. Key Findings / Summary
- 9.2. Market Analysis – By Type of Leukemia
- 9.2.1. Chronic Myeloid Leukemia (CML)
- 9.2.2. Chronic Lymphocytic Leukemia (CLL)
- 9.2.3. Acute Lymphocytic Leukemia (ALL)
- 9.2.4. Acute Myeloid Leukemia (AML)
- 9.2.5. Others
- 9.3. Market Analysis – By Treatment Type
- 9.3.1. Chemotherapy
- 9.3.2. Targeted Therapy
- 9.3.3. Immunotherapy
- 9.3.4. Others
- 9.4. Market Analysis – By Route of Administration
- 9.4.1. Injectable Mode
- 9.4.2. Oral Mode
- 9.5. Market Analysis – By Distribution Channel
- 9.5.1. Hospital Pharmacies
- 9.5.2. Retail Pharmacies
- 9.5.3. Others
- 9.6. Market Analysis – By Country/Sub-Region
- 9.6.1. Brazil
- 9.6.2. Mexico
- 9.6.3. Rest of Latin America
- 10. Middle East & Africa Leukemia Therapeutics Market Analysis, Insights and Forecast, 2016-2027
- 10.1. Key Findings / Summary
- 10.2. Market Analysis – By Type of Leukemia
- 10.2.1. Chronic Myeloid Leukemia (CML)
- 10.2.2. Chronic Lymphocytic Leukemia (CLL)
- 10.2.3. Acute Lymphocytic Leukemia (ALL)
- 10.2.4. Acute Myeloid Leukemia (AML)
- 10.2.5. Others
- 10.3. Market Analysis – By Treatment Type
- 10.3.1. Chemotherapy
- 10.3.2. Targeted Therapy
- 10.3.3. Immunotherapy
- 10.3.4. Others
- 10.4. Market Analysis – By Route of Administration
- 10.4.1. Injectable Mode
- 10.4.2. Oral Mode
- 10.5. Market Analysis – By Distribution Channel
- 10.5.1. Hospital Pharmacies
- 10.5.2. Retail Pharmacies
- 10.5.3. Others
- 10.6. Market Analysis – By Country/Sub-Region
- 10.6.1. GCC Countries
- 10.6.2. South Africa
- 10.6.3. Rest of Middle East & Africa
- 11. Competitive Analysis
- 11.1. Key Industry Developments
- 11.2. Global Market Share Analysis (2019)
- 11.3. Competition Dashboard
- 11.4. Comparative Analysis – Major Players
- 11.5. Company Profiles (Overview, Products, SWOT analysis, Recent developments, strategies, financials (based on availability))
- 11.5.1. Pfizer Inc.
- 11.5.1.1. Overview,
- 11.5.1.2. Products,
- 11.5.1.3. SWOT analysis,
- 11.5.1.4. Recent developments,
- 11.5.1.5. strategies,
- 11.5.1.6. financials (based on availability)
- 11.5.2. Novartis
- 11.5.2.1. Overview,
- 11.5.2.2. Products,
- 11.5.2.3. SWOT analysis,
- 11.5.2.4. Recent developments,
- 11.5.2.5. strategies,
- 11.5.2.6. financials (based on availability)
- 11.5.3. Sanofi/ Genzyme Corporation
- 11.5.3.1. Overview,
- 11.5.3.2. Products,
- 11.5.3.3. SWOT analysis,
- 11.5.3.4. Recent developments,
- 11.5.3.5. strategies,
- 11.5.3.6. financials (based on availability)
- 11.5.4. Lupin Ltd.
- 11.5.4.1. Overview,
- 11.5.4.2. Products,
- 11.5.4.3. SWOT analysis,
- 11.5.4.4. Recent developments,
- 11.5.4.5. strategies,
- 11.5.4.6. financials (based on availability)
- 11.5.5. Amgen Inc.
- 11.5.5.1. Overview,
- 11.5.5.2. Products,
- 11.5.5.3. SWOT analysis,
- 11.5.5.4. Recent developments,
- 11.5.5.5. strategies,
- 11.5.5.6. financials (based on availability)
- 11.5.6. AbbVie
- 11.5.6.1. Overview,
- 11.5.6.2. Products,
- 11.5.6.3. SWOT analysis,
- 11.5.6.4. Recent developments,
- 11.5.6.5. strategies,
- 11.5.6.6. financials (based on availability)
- 11.5.7. Johnson & Johnson Services, Inc.
- 11.5.7.1. Overview,
- 11.5.7.2. Products,
- 11.5.7.3. SWOT analysis,
- 11.5.7.4. Recent developments,
- 11.5.7.5. strategies,
- 11.5.7.6. financials (based on availability)
- 11.5.8. Bristol-Myers Squibb
- 11.5.8.1. Overview,
- 11.5.8.2. Products,
- 11.5.8.3. SWOT analysis,
- 11.5.8.4. Recent developments,
- 11.5.8.5. strategies,
- 11.5.8.6. financials (based on availability)
- 11.5.9. F. Hoffmann-La Roche
- 11.5.9.1. Overview,
- 11.5.9.2. Products,
- 11.5.9.3. SWOT analysis,
- 11.5.9.4. Recent developments,
- 11.5.9.5. strategies,
- 11.5.9.6. financials (based on availability)
- 11.5.10. Takeda Pharmaceutical Co Ltd
- 11.5.10.1. Overview,
- 11.5.10.2. Products,
- 11.5.10.3. SWOT analysis,
- 11.5.10.4. Recent developments,
- 11.5.10.5. strategies,
- 11.5.10.6. financials (based on availability)
- 11.5.11. Sanofi/ Genzyme Corporation
- 11.5.11.1. Overview,
- 11.5.11.2. Products,
- 11.5.11.3. SWOT analysis,
- 11.5.11.4. Recent developments,
- 11.5.11.5. strategies,
- 11.5.11.6. financials (based on availability)
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
